Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N E Kay

Showing results (121-130 of 149) with videos related to

Pageof 15
Sort By:
Leukemia|February 11, 2005
VEGF receptors on chronic lymphocytic leukemia (CLL) B cells interact with STAT 1 and 3: implication for apoptosis resistanceY K Lee, T D Shanafelt, N D Bone, et al.
American Journal of Hematology|August 1, 1986
Lymphoblastic transformation of myelodysplastic syndromeJ L Ascensao, N E Kay, J J Wright, et al.
British Journal of Haematology|March 21, 1998
T-helper phenotypes in the blood of myeloma patients on ECOG phase III trials E9486/E3A93N E Kay, T Leong, N Bone, et al.
Blood|July 1, 1997
Circulating blood B cells in multiple myeloma: analysis and relationship to circulating clonal cells and clinical parameters in a cohort of patients entered on the Eastern Cooperative Oncology Group phase III E9486 clinical trialN E Kay, T Leong, R A Kyle, et al.
Leukemia & Lymphoma|October 8, 1999
Is flow cytometric DNA content hypodiploidy prognostic in multiple myeloma?P R Greipp, M C Trendle, T Leong, et al.
Leukemia Research|December 6, 2005
Clinical effects of oral green tea extracts in four patients with low grade B-cell malignanciesT D Shanafelt, Y K Lee, T G Call, et al.
British Journal of Haematology|June 10, 2000
Prognostic value of serum markers of bone metabolism in untreated multiple myeloma patientsR Fonseca, M C Trendle, T Leong, et al.
Blood|October 1, 1996
Activating mutations of N- and K-ras in multiple myeloma show different clinical associations: analysis of the Eastern Cooperative Oncology Group Phase III TrialP Liu, T Leong, L Quam, et al.
Leukemia & Lymphoma|February 1, 1996
Complete remission induction with combined VBMCP chemotherapy and interferon (rIFN alpha 2b) in patients with multiple myelomaM M Oken, R A Kyle, P R Greipp, et al.
Cancer|September 24, 1999
The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486M M Oken, T Leong, R E Lenhard, et al.
Pageof 15

Showing results (121-130 of 149) with videos related to

Sort By:
Pageof 15
Leukemia|February 11, 2005
VEGF receptors on chronic lymphocytic leukemia (CLL) B cells interact with STAT 1 and 3: implication for apoptosis resistanceY K Lee, T D Shanafelt, N D Bone, et al.
American Journal of Hematology|August 1, 1986
Lymphoblastic transformation of myelodysplastic syndromeJ L Ascensao, N E Kay, J J Wright, et al.
British Journal of Haematology|March 21, 1998
T-helper phenotypes in the blood of myeloma patients on ECOG phase III trials E9486/E3A93N E Kay, T Leong, N Bone, et al.
Blood|July 1, 1997
Circulating blood B cells in multiple myeloma: analysis and relationship to circulating clonal cells and clinical parameters in a cohort of patients entered on the Eastern Cooperative Oncology Group phase III E9486 clinical trialN E Kay, T Leong, R A Kyle, et al.
Leukemia & Lymphoma|October 8, 1999
Is flow cytometric DNA content hypodiploidy prognostic in multiple myeloma?P R Greipp, M C Trendle, T Leong, et al.
Leukemia Research|December 6, 2005
Clinical effects of oral green tea extracts in four patients with low grade B-cell malignanciesT D Shanafelt, Y K Lee, T G Call, et al.
British Journal of Haematology|June 10, 2000
Prognostic value of serum markers of bone metabolism in untreated multiple myeloma patientsR Fonseca, M C Trendle, T Leong, et al.
Blood|October 1, 1996
Activating mutations of N- and K-ras in multiple myeloma show different clinical associations: analysis of the Eastern Cooperative Oncology Group Phase III TrialP Liu, T Leong, L Quam, et al.
Leukemia & Lymphoma|February 1, 1996
Complete remission induction with combined VBMCP chemotherapy and interferon (rIFN alpha 2b) in patients with multiple myelomaM M Oken, R A Kyle, P R Greipp, et al.
Cancer|September 24, 1999
The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486M M Oken, T Leong, R E Lenhard, et al.
Pageof 15